Dr. Guoqing Wei 魏国庆
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of leukemia, lymphoma, multiple myeloma, anemia, and bleeding disorders. Hematopoietic stem cell transplantation for malignant blood diseases.
Dr. Wei earned a medical degree from Henan Medical University in 1998 and a PhD in hematology from Zhejiang University in 2004. Since 2004, Dr. Wei has worked at the Hematology and Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine. From June 2010 to November 2011, Dr. Wei was a visiting scholar at Westchester Medical Center, New York Medical College. Dr. Wei has participated in over 10 research projects and published more than 20 papers.
Professional roles
- Member, Zhejiang Branch of Chinese Medical Association
- Standing Committee Member, Hematology Branch of Zhejiang Immunological Society
- Member, Hematology Branch of Zhejiang Medical Association
- Standing Committee Member, China Precision Medicine Management Society
Name order: in Chinese the family name comes first (Wei Guoqing). Papers usually list the name as Guoqing Wei or Wei G.
Selected publications
67 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transplant Cell Ther, 2026 (senior author): Corrigendum to <Long-Term Follow-Up of CD19 CAR-T for R/R B-NHL: Ki-67 as a Prognostic Factor for Sustained Remission> <[Transplantation and cellular therapy, 32(8), 952.e1-952.e15.]>. PubMed 42785377
- Transplant Cell Ther, 2026 (senior author): Long-Term Follow-Up of CD19 CAR-T for R/R B-NHL: Ki-67 as a Prognostic Factor for Sustained Remission. PubMed 42134593
- Cytotherapy, 2026 (senior author): Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. PubMed 41830735
- NPJ Precis Oncol, 2026 (senior author): CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy. PubMed 41963478
- BMC Med, 2026 (senior author): Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study. PubMed 41776492
- Mol Biol Rep, 2024 (senior author): A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome. PubMed 38643442
- J Immunother Cancer, 2023 (senior author): Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. PubMed 36808074
- Exp Hematol Oncol, 2012 (first author): Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. PubMed 23210632
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion